G-BA: Orphan Signifor has 'marginal' additional benefit

Germany's Federal Joint Committee (G-BA) issued a final assessment that said Signifor pasireotide from Novartis AG

Read the full 166 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE